•  
  • 中华人民共和国国家卫生健康委员会 主管
  • 中国医学科学院 主办
杂志信息/Information
  • 刊名:癌症进展
  • Oncology Progress Journal
  • 主管:国家卫生健康委员会
  • 主办:中国医学科学院
  • 社长:袁钟
  • 主编:赵平
  • 编辑部主任:骆春瑶
  • 编辑部副主任:陈闻
  • 编辑出版:中国协和医科大学出版社
    《癌症进展》编辑部
    100730,北京东单三条9号
    电话:(010) 65264353
    E-mail:azjzzz@163.com
    http://www.aizhengjinzhan.com
  • 市场运营:惠生文化传媒(北京)有限公司
    李长松 沈杰
  • 印刷:北京联合互通彩色印刷有限公司
  • 国内统一连续出版物号:CN 11-4971/R
  • 国际标准连续出版物号ISSN 1672-1535
  • 广告许可证:京东工商广字第0342号
下载专区/Download
订阅电子期刊/Subscribe

提交您的邮箱地址,我们会定期将电子期刊 发送到您的邮箱

期刊检索/Journal Search
扫一扫,关注

过刊目录

2016 年第 2 期 第 14 卷

多西紫杉醇联合顺铂辅助化疗对非小细胞肺癌的疗效及毒副作用影响

作者:

单位:

关键词:多西紫杉醇顺铂化疗非小细胞肺癌

  • 摘要:
  • 【摘要】目的:探究多西紫杉醇联合顺铂辅助化疗对非小细胞肺癌的疗效以及毒副作用的影响。方法:回顾性分析2011年1月-2014年12月本院诊治的164例非小细胞肺癌患者临床资料,按照不同治疗方式分为两组(各82例),两组均接受手术治疗,在此基础上,对照组采用多西紫杉醇治疗,研究组采用多西紫杉醇联合顺铂治疗,对比两组近期治疗有效率,毒副反应发生率以及功能状态改善情况。结果:研究组近期总有效率51.22%显著高于对照组29.26%(P<0.05);两组发生的各项毒副反应(如:恶心呕吐、疲乏无力、白细胞减少等)率均相当(P>0.05);研究组在两组治疗后功能状态评分均得到显著提高基础上,其提高幅度更大(P<0.05,P<0.01);两组患者1、2年的生存率比较均无明显差异(P>0.05)。结论:多西紫杉醇联合顺铂辅助化疗对非小细胞肺癌的疗效甚佳,并且不会增加毒副反应,此外还可以改善患者功能状态,具有临床实际应用价值。
  • Objective: To explore the therapeutic effect of Docetaxel combined with Cisplatin chemotherapy in the treatment of non-small cell lung cancer and its side effects. Methods: The clinical data of 164 patients treated for non-small cell lung cancer in our hospital between January 2011 and December 2014 were reviewed. The patients were, according to the different treatments given, divided into two groups (each with 82 cases), with the control group using Docetaxel for treatment and the study group receiving Docetaxel combined with Cisplatin chemotherapy for treatment. The total effective rate of recent treatment, incidence of adverse reactions and the improvement on functional performance of the two groups were observed and contrasted. Results: The total effective rate of recent treatment in the study group was 51.22%, significantly higher than that in control group, which was 29.26% (P<0.05). Yet, there was no difference registered in the incidence of each index of adverse reactions (such as nausea and vomiting, increased temperature, leukopenia and so on) (P>0.05). The functional scoring of both groups was significantly improved after the treatment, and the study group improved more significantly (P<0.05, P<0.01). Conclusion: Docetaxel combined with Cisplatin chemotherapy is with significant effect in the treatment of non-small cell lung cancer, which will not increase the incidence of adverse reaction yet improves the functional status of the patients. Therefore, it is with practical value for clinical application.